Mechanisms to explain the overshoot in bone remodeling markers after denosumab discontinuation: are we there yet?
作者信息
Ramchand Sabashini K, McDonald Michelle M
机构信息
Endocrinology and Metabolism Institute, Cleveland Clinic, Lerner College of Medicine - Case Western Reserve University, 9500 Euclid Ave, Cleveland, OH 44195, United States.
School of Medical Science, Faculty of Medicine and Health, The University of Sydney, The Charles Perkins Centre D17, John Hopkins Drive, Australia.
出版信息
J Bone Miner Res. 2025 Mar 15;40(3):299-300. doi: 10.1093/jbmr/zjaf007.
Abstract
摘要
相似文献
1
Mechanisms to explain the overshoot in bone remodeling markers after denosumab discontinuation: are we there yet?解释地诺单抗停药后骨重塑标志物超调现象的机制：我们做到了吗？
J Bone Miner Res. 2025 Mar 15;40(3):299-300. doi: 10.1093/jbmr/zjaf007.
2
The effects of denosumab on osteoclast precursors in postmenopausal women: a possible explanation for the overshoot phenomenon after discontinuation.地诺单抗对绝经后女性破骨细胞前体的影响：停药后过冲现象的一种可能解释。
J Bone Miner Res. 2025 Mar 15;40(3):301-306. doi: 10.1093/jbmr/zjae170.
3
Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation.成骨细胞中骨保护素表达减少可能导致 denosumab 停药后反弹性吸收。
JCI Insight. 2023 Sep 22;8(18):e167790. doi: 10.1172/jci.insight.167790.
4
Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation.地舒单抗治疗期间骨硬度升高，停药期间破骨细胞活性持续降低。
Front Endocrinol (Lausanne). 2020 May 15;11:250. doi: 10.3389/fendo.2020.00250. eCollection 2020.
5
Temporal patterns of osteoclast formation and activity following withdrawal of RANKL inhibition.阻断核因子 κB 受体激活剂配体（RANKL）后破骨细胞形成和活性的时间模式。
J Bone Miner Res. 2024 May 2;39(4):484-497. doi: 10.1093/jbmr/zjae023.
6
Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation.破骨细胞再循环与地舒单抗停药后的反弹现象。
Curr Osteoporos Rep. 2022 Dec;20(6):505-515. doi: 10.1007/s11914-022-00756-5. Epub 2022 Oct 6.
7
Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition.早期多次给予唑来膦酸盐可减轻核因子κB受体活化因子配体抑制作用撤除后的骨质流失反弹。
J Bone Miner Res. 2025 Mar 15;40(3):413-427. doi: 10.1093/jbmr/zjaf008.
8
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.地舒单抗治疗骨质疏松症的停药：ECTS 的系统评价和立场声明。
Bone. 2017 Dec;105:11-17. doi: 10.1016/j.bone.2017.08.003. Epub 2017 Aug 5.
9
Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.地诺单抗停用后与反弹相关的椎体骨折——来自临床和生物力学研究
Osteoporos Int. 2016 May;27(5):1917-21. doi: 10.1007/s00198-015-3458-6. Epub 2015 Dec 22.
10
The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial.地舒单抗（CARD）研究后阿仑膦酸钠和雷洛昔芬的比较：一项比较疗效试验。
Osteoporos Int. 2024 Feb;35(2):255-263. doi: 10.1007/s00198-023-06932-2. Epub 2023 Oct 6.
本文引用的文献
1
Cellular signatures in human blood track bone mineral density in postmenopausal women.人类血液中的细胞特征可追踪绝经后妇女的骨密度。
JCI Insight. 2024 Nov 22;9(22):e178977. doi: 10.1172/jci.insight.178977.
2
The effects of denosumab on osteoclast precursors in postmenopausal women: a possible explanation for the overshoot phenomenon after discontinuation.地诺单抗对绝经后女性破骨细胞前体的影响：停药后过冲现象的一种可能解释。
J Bone Miner Res. 2025 Mar 15;40(3):301-306. doi: 10.1093/jbmr/zjae170.
3
Temporal patterns of osteoclast formation and activity following withdrawal of RANKL inhibition.阻断核因子 κB 受体激活剂配体（RANKL）后破骨细胞形成和活性的时间模式。
J Bone Miner Res. 2024 May 2;39(4):484-497. doi: 10.1093/jbmr/zjae023.
4
Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation.成骨细胞中骨保护素表达减少可能导致 denosumab 停药后反弹性吸收。
JCI Insight. 2023 Sep 22;8(18):e167790. doi: 10.1172/jci.insight.167790.
5
Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption.在RANKL刺激的骨吸收过程中，破骨细胞通过骨形态细胞进行循环利用。
Cell. 2021 Apr 1;184(7):1940. doi: 10.1016/j.cell.2021.03.010.
6
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.地舒单抗停药后发生的椎体骨折：一项 FREEDOM 随机安慰剂对照试验及其延伸的事后分析。
J Bone Miner Res. 2018 Feb;33(2):190-198. doi: 10.1002/jbmr.3337. Epub 2017 Nov 22.
7
Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment.停用地诺单抗治疗后，椎体骨折患者的破骨细胞生成增加。
Eur J Endocrinol. 2017 Jun;176(6):677-683. doi: 10.1530/EJE-16-1027. Epub 2017 Mar 10.
8
Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.地舒单抗治疗及其停药对低骨量绝经后妇女骨密度和骨转换标志物的影响。
J Clin Endocrinol Metab. 2011 Apr;96(4):972-80. doi: 10.1210/jc.2010-1502. Epub 2011 Feb 2.
9
Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.odanacatib 治疗绝经后低骨密度妇女：三年持续治疗和疗效持续。
J Bone Miner Res. 2011 Feb;26(2):242-51. doi: 10.1002/jbmr.212.
10
Denosumab for prevention of fractures in postmenopausal women with osteoporosis.地诺单抗预防绝经后骨质疏松症女性骨折
N Engl J Med. 2009 Aug 20;361(8):756-65. doi: 10.1056/NEJMoa0809493. Epub 2009 Aug 11.
Zotero 插件